Unexpected toxicity of CDK4/6 inhibitor palbociclib and radiotherapy

BACKGROUND: Cyclin‐dependent kinase (CDK) 4/6 inhibitors have recently been approved for the treatment of hormone receptor–positive and HER2‐negative metastatic breast cancer in association with endocrine therapy in postmenopausal women. Data on the interaction of CDK4/6 inhibition and radiotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: van Aken, Evert S. M., Beeker, Aart, Houtenbos, Ilse, Pos, Floris J., Linn, Sabine C., Elkhuizen, Paula H. M., de Jong, Monique C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842704/
https://www.ncbi.nlm.nih.gov/pubmed/34145976
http://dx.doi.org/10.1002/cnr2.1470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842704/
https://www.ncbi.nlm.nih.gov/pubmed/34145976
http://dx.doi.org/10.1002/cnr2.1470

Ejemplares similares